



Patient ID SA00178350	Patient Name TESTINGRNV, REPORTS A	Birth Date 1964-11-11	Sex M	Age 61
Order Number SA00178350	Client Order Number SA00178350	Ordering Physician CLIENT,CLIENT	Report Notes	
Account Information C7028846 DLMP Rochester		Collected 24 Nov 2025 00:00		

Alzheimer's Disease Evaluation, CSF

p-Tau/Abeta42



0.125 ratio

SDL

Reference Value
≤0.028

AD Interpretation

The elevated p-Tau/Abeta42 ratio is consistent with the presence of pathological changes associated with Alzheimer's disease.

The p-Tau/Abeta42 ratio provides better concordance with amyloid Positron Emission Tomography (PET) imaging when compared to Abeta42, phospho-Tau and total-Tau individually. A cut-off of 0.028 provides optimal balance between negative % agreement (NPA) and positive % agreement (PPA) when compared to amyloid PET results. A p-Tau/Abeta42 ratio of ≤0.028 has a 92% NPA with normal amyloid PET. A ratio of >0.028 has a 92% PPA with abnormal amyloid PET.

Failure to adhere to the sample collection instructions provided in the Lab Test Catalog may result in falsely reduced Abeta42 concentrations; potentially affecting subsequent interpretations as well as the p-Tau/Abeta42 ratio.

The p-Tau assay measures p-Tau181 (Tau phosphorylated at threonine 181).

ADDITIONAL INFORMATION

The testing method is an electrochemiluminescence assay manufactured by Roche Diagnostics Inc.

Values obtained with different assay methods or kits may be different and cannot be used interchangeably.

Abeta42



200 pg/mL

SDL

Reference Value
>834

ADDITIONAL INFORMATION

The testing method is an electrochemiluminescence assay manufactured by Roche Diagnostics Inc.

Values obtained with different assay methods or kits may be different and cannot be used interchangeably.

Total-Tau



250 pg/mL

1 SDL

Reference Value
≤238

ADDITIONAL INFORMATION

The testing method is an electrochemiluminescence assay manufactured by Roche Diagnostics Inc.

Values obtained with different assay methods or kits may be different and cannot be used interchangeably.

Phospho-Tau(181P)



25.0 pg/mL

SDL

Reference Value
≤21.6

ADDITIONAL INFORMATION

The testing method is an electrochemiluminescence assay manufactured by Roche Diagnostics Inc.

Values obtained with different assay methods or kits may be different and cannot be used interchangeably.

Received: 25 Nov 2025 16:00

Reported: 25 Nov 2025 16:00

Performing Site Legend

Code	Laboratory	Address	Lab Director	CLIA Certificate
SDL	Mayo Clinic Laboratories - Rochester Superior Drive	3050 Superior Drive NW, Rochester MN 55905	Nikola Baumann Ph.D.	24D1040592



Patient ID SA00178350	Patient Name TESTINGRNA, REPORTS A	Birth Date 1964-11-11	Sex M	Age 61
Order Number SA00178350	Client Order Number SA00178350	Ordering Physician CLIENT,CLIENT	Report Notes	
Account Information C7028846 DLMP Rochester		Collected 24 Nov 2025 00:00		

Test
Environment
LTCSEQ Template

Laboratory Notes

- 1 This test has been modified from the manufacturer's instructions. Its performance characteristics were determined by Mayo Clinic in a manner consistent with CLIA requirements. This test has not been cleared or approved by the U.S. Food and Drug Administration.

Performing Site Legend

Code	Laboratory	Address	Lab Director	CLIA Certificate
SDL	Mayo Clinic Laboratories - Rochester Superior Drive	3050 Superior Drive NW, Rochester MN 55905	Nikola Baumann Ph.D.	24D1040592